Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reck

Showing results (901-910 of 1,518) with videos related to

Pageof 152
Sort By:
Versicherungsmedizin|April 6, 2002
[Freiburg intervention program for ambulatory therapy of obesity in childhood (FITOC)]U Korsten-Reck, C Rudloff, R Kayser, et al.
Clinical Lung Cancer|October 10, 2006
Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancerWolfgang Schuette, Thomas Blankenburg, Claus-Peter Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2009
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAilMartin Reck, Joachim von Pawel, Petr Zatloukal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2010
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)M Reck, J von Pawel, P Zatloukal, et al.
Biochemical and Biophysical Research Communications|February 24, 2011
Cancer stem cell-like cells from a single cell of oral squamous carcinoma cell linesO Felthaus, T Ettl, M Gosau, et al.
Journal of Reproductive Immunology|August 4, 2004
Cytokines in recurrent pregnancy lossSilvia Daher, Kátia de Arruda Geraldes Denardi, Maria Heloísa Souza Lima Blotta, et al.
Lung Cancer (Amsterdam, Netherlands)|May 5, 2009
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancerMark J McKeage, Martin Reck, Michael B Jameson, et al.
Environmental Science and Pollution Research International|May 21, 2017
Effect of tannery effluent on oxidative status of brain structures and liver of rodentsFelipe Dos Santos Moysés, Karine Bertoldi, Viviane Rostirola Elsner, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 7, 2018
Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESSE Arriola, A Paredes-Lario, R García-Gomez, et al.
Research Quarterly for Exercise and Sport|September 8, 2020
Correlation Between Inflammatory and Epigenetic Marks With Aerobic Performance in 10-km RunnersIonara Rodrigues Siqueira, Carla Giovana Basso, Lolita Schneider Pizzolato, et al.
Pageof 152

Showing results (901-910 of 1,518) with videos related to

Sort By:
Pageof 152
Versicherungsmedizin|April 6, 2002
[Freiburg intervention program for ambulatory therapy of obesity in childhood (FITOC)]U Korsten-Reck, C Rudloff, R Kayser, et al.
Clinical Lung Cancer|October 10, 2006
Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancerWolfgang Schuette, Thomas Blankenburg, Claus-Peter Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2009
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAilMartin Reck, Joachim von Pawel, Petr Zatloukal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2010
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)M Reck, J von Pawel, P Zatloukal, et al.
Biochemical and Biophysical Research Communications|February 24, 2011
Cancer stem cell-like cells from a single cell of oral squamous carcinoma cell linesO Felthaus, T Ettl, M Gosau, et al.
Journal of Reproductive Immunology|August 4, 2004
Cytokines in recurrent pregnancy lossSilvia Daher, Kátia de Arruda Geraldes Denardi, Maria Heloísa Souza Lima Blotta, et al.
Lung Cancer (Amsterdam, Netherlands)|May 5, 2009
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancerMark J McKeage, Martin Reck, Michael B Jameson, et al.
Environmental Science and Pollution Research International|May 21, 2017
Effect of tannery effluent on oxidative status of brain structures and liver of rodentsFelipe Dos Santos Moysés, Karine Bertoldi, Viviane Rostirola Elsner, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 7, 2018
Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESSE Arriola, A Paredes-Lario, R García-Gomez, et al.
Research Quarterly for Exercise and Sport|September 8, 2020
Correlation Between Inflammatory and Epigenetic Marks With Aerobic Performance in 10-km RunnersIonara Rodrigues Siqueira, Carla Giovana Basso, Lolita Schneider Pizzolato, et al.
Pageof 152